by The Associated Press Posted Jul 16, 2013 8:19 am MDT AddThis Sharing ButtonsShare to TwitterTwitterShare to FacebookFacebookShare to RedditRedditShare to 電子郵件Email Johnson & Johnson 2Q profit jumps on higher sales vs. 2012 quarter hurt by huge charges NEW BRUNSWICK, N.J. – Johnson & Johnson says its second-quarter profit more than doubled on higher sales of medicines and medical devicesThe maker of Tylenol, prescription drugs and medical devices handily beat Wall Street expectation.New Brunswick, N.J.-based J&J says net income was $3.83 billion, or $1.33 per share, up from $1.41 billion, or 50 cents per share. Last year’s quarter was weighed down by big charges.Excluding one-time items, net income was $4.29 billion, or $1.48 per share.Revenue was $17.88 billion, up 8.5 per cent from $16.48 billion a year earlier.Analysts polled by FactSet were expecting earnings per share of $1.39 and sales of $17.72 billion.The company raised its profit forecast to $5.40 to $5.47 per share, excluding items. In January, J&J predicted earnings of $5.35 to $5.45 per share.
← Previous Story KING ŠARIĆ: FC Barcelona to fight for the title at EHF CL F4! Next Story → Veszprem will play for the trophy after 13 years! The Man of the Match of the first semi-final in Cologne was Barca’s goalkeeper Danijel Šarić. He pointed out the biggest reason of the victory of his team in Lanxess Arena:– Our defense did the job well. We have good counter-attack and “fast center”. Kielce is great team with a lot of experienced Polish NT players. I didn’t expect that would be easy, that’s why the most important thing is that we broke them in the finish and reached the final – concluded Šarić.FC Barcelona beat Vive Tauron Kielce 33:28 in the first-semi-final of the VELUX EHF Champions League Final4.